Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | BRSK1 | Q8TDC3 | 1/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL429184 | 0.78 | KDM1A (0.43) | KDM1APIK3CAPDE10ATSHRHSD17B10 | |
| SCHEMBL423639 | 0.74 | HIF1A (0.51) | KDM1APIK3CAPDE10ATSHRHSD17B10 | |
| SCHEMBL428014 | 0.73 | KDM1A (0.45) | KDM1APDE10ASYKTSHRMAPK1 | |
| SCHEMBL30854964 | 0.71 | CXCR4 (0.64) | PIK3CBACHEPKMTSHRALOX15 | |
| SCHEMBL426194 | 0.70 | KDM1A (0.42) | KDM1APDE10ATSHRHSD17B10ALOX15 | |
| SCHEMBL28518369 | 0.69 | KDM1A (0.57) | KDM1AACHEPDE10AMETAP1KDM4E | |
| SCHEMBL425631 | 0.69 | ALDH1A1 (0.51) | PIK3CAPDE10ATSHRALOX15MAPK1 | |
| SCHEMBL425565 | 0.68 | TYK2 (0.54) | PIK3CBPIK3CAPDE10ATYK2SYK | |
| SCHEMBL426132 | 0.68 | CYP3A4 (0.46) | PIK3CAPDE10ATSHRHSD17B10MAPK1 | |
| SCHEMBL426801 | 0.68 | ALDH1A1 (0.45) | PDE10ATSHRALOX15MAPK1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615552-B2 | Fused heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-10 | — | — | US | claimed |
| US-20090253694-A1 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-08 | — | — | US | claimed |
| EP-1687002-A4 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2008-07-23 | — | — | EP | claimed |
| JP-2007510745-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-04-28 | — | — | US | disclosed |
| US-7615552-B2 | Fused heterocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-11-10 | — | — | US | disclosed |
| US-20090253694-A1 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-08 | — | — | US | disclosed |
| EP-1687002-A4 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250770-A1 | Fused heterocyclic compounds | IL2, IL4, IL15 | KDM1A 3005/4885PIK3CB 2333/4885PIK3CA 2415/4885 |
| US-20090253694-A1 | Fused hetrocyclic compounds | IL2, IL15, IL4 | KDM1A 3546/4885PIK3CB 1469/4885PIK3CA 1307/4885 |
| US-20110098267-A1 | TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS | IL17A, IL23R, IL15 | KDM1A 3101/4885PIK3CB 2249/4885PIK3CA 2168/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | KDM1A 1011/4885PIK3CB 2892/4885PIK3CA 4463/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | KDM1A 1011/4885PIK3CB 2892/4885PIK3CA 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.